Abstract
Introduction A history of malignancy has been considered as a contraindication for heart transplantation. The number of patients with prior malignancy needing transplantation is increasing due to improved survival and to cardiotoxic cancer treatment. However, this reluctance for transplantation can be challenged by the already available results.
Methods A systematic literature search was performed in electronic databases. After exclusion of cardiac sarcomas, three case reports, thirteen series of which three are paediatric, two database searches and one article with specifi c design have been found. The larger series are of more recent origin. The study design of the manuscripts diff ered to some degree.
Results The preoperative profi le and the postoperative results are reviewed. The preoperative profi le includes demographics, interval between treatment of malignancy and transplantation, indication of transplantation and diff erences between patients with and without prior malignancy. An important observation is the increase of transplantation in patients with chemotherapy-related cardiomyopathy over time. The postoperative results show that hospital mortality and long-term survival do not diff er signifi cantly between patients with and without pre-transplant malignancy. This seems also to be true for post-transplant recurrence. The disease-free pre-transplant interval has a major eff ect on both outcomes. Patients with haematologic malignancies and after splenectomy have a worse prognosis. Use of LVAD (left ventricular assist device) as bridge-to-transplant and rapamycin as immune suppression, holds some promises.
Conclusions This review has some limitations since the published series are not comparable. It seems that transplantation in patients with prior malignancy can be justifi ed in some cases, especially when the interval between malignancy and transplantation exceeds fi ve years.